Title

Successfully targeting triple negative breast cancer using combination therapy of didox and doxorubicin with reduced cardiotoxicity

Lead Author Affiliation

Physiology & Pharmacology

Introduction

Triple-negative breast cancer (TNBC) is an aggressive histological subtype that has limited treatment options with chemotherapy being the only systemic therapy for these patients. The most common chemotherapy regimen used includes the anthracycline Doxorubicin (DOXO). Although DOXO is a highly effective agent, its efficacy is limited due to acquired drug resistance and cardiotoxicity.

Location

DUC Ballroom A&B

Format

Poster Presentation

This document is currently not available here.

Share

COinS
 
Apr 30th, 1:00 PM Apr 30th, 3:30 PM

Successfully targeting triple negative breast cancer using combination therapy of didox and doxorubicin with reduced cardiotoxicity

DUC Ballroom A&B

Triple-negative breast cancer (TNBC) is an aggressive histological subtype that has limited treatment options with chemotherapy being the only systemic therapy for these patients. The most common chemotherapy regimen used includes the anthracycline Doxorubicin (DOXO). Although DOXO is a highly effective agent, its efficacy is limited due to acquired drug resistance and cardiotoxicity.